Skip to main content
logo
Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.070
-0.190 (-4.46%)
At close: Mar 30, 2026, 4:00 PM EDT
4.070
0.00 (0.00%)
After-hours: Mar 30, 2026, 4:10 PM EDT

Orchestra BioMed Holdings Revenue

In the year 2025, Orchestra BioMed Holdings had annual revenue of $33.48M with 1,169.22% growth. Orchestra BioMed Holdings had revenue of $30.92M in the quarter ending December 31, 2025, with 12,120.16% growth.

Revenue (ttm)
$33.48M
Revenue Growth
+1,169.22%
P/S Ratio
7.22
Revenue / Employee
$389,326
Employees
86
Market Cap
238.18M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202533.48M30.84M1,169.22%
Dec 31, 20242.64M-122.00K-4.42%
Dec 31, 20232.76M-773.00K-21.88%
Dec 31, 20223.53M4.32M-
Dec 31, 2021-782.00K-6.49M-
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Cellectis79.59M
Coherus Oncology42.17M
Voyager Therapeutics40.37M
C4 Therapeutics35.95M
Sol-Gel Technologies19.39M
OmniAb18.67M
Abeona Therapeutics5.82M
Silence Therapeutics559.00K
Revenue Rankings

OBIO News

More News